Oh but wait, sorry FY20 EBIT is depressed by one off impairment of a product, D&A is counted in Cost of sales. 56.2m of D&A attributed to CX140 product impairment. D&A was 284.4 in FY20 compared to 209.1m in FY19. In HY21 D&A is 103.7m so circa 200m annulalised like FY19.
Well, lets add back 80m odd to the FY20 'operational EBIT' because D&A is in cost of sales and was 'one off' inflated in FY20.
Capital Raising, page-14
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$285.54 |
Change
-1.120(0.39%) |
Mkt cap ! $138.2B | |||
| Open | High | Low | Value | Volume |
| $285.50 | $285.86 | $282.18 | $110.7M | 388.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 368 | $285.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $285.54 | 425 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |